Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News information

Medicilon sponsored the seminar on new drug preclinical research and IND application strategy

2018-05-29
|
Page View:

On May 24, 2018, the “20th Shanghai International Biotechnology and Medicine Symposium-Symposium on New Drug Preclinical Research and IND Application Strategies” hosted by Medicilon officially came to an end at the Shanghai International Convention Center! This meeting was supported and recognized by more than two hundred colleagues in the biomedical industry. At the same time, I was honored to invite Gao Chenyan, Minister of the Clinical Department of Biological Products, National Center for Drug Evaluation, Ms. Ruan Xiufang, Shanghai Food and Drug Administration, and Shanghai Ze Dr. Shi Li of Run Biotech Co., Ltd., Dr. Yu Qiang of Shengshi Tyco Biomedical Technology (Suzhou) Co., Ltd., Dr. Yongxin Zhao from Hangzhou Duoxi Biotechnology Co., Ltd., Dr. Xiaobin Zhao from The WhiteOak Group, and Dr. Xiaobin Zhao from Shanghai Medicilon Co., Ltd. Dr. Chunlin Chen, Dr. Xingchu Gu, Dr. Jianguo Ma, Dr. Feng Ren, etc. The purpose of this conference is to exchange new drug preclinical research and development experience and IND application strategies, discuss the current new drug research and development environment and future opportunities and challenges, with a view to promoting the healthy development of my country’s new drug research and development industry.

review of the conference-seminar on new drug preclinical research and IND application strategy
Wonderful review of the conference

Conference sign-in
Conference sign-in
Dr. Feng Ren, Vice President of Medicilon's Chemical Department, gave a welcome speech to the guests, and the conference officially began!
Dr. Feng Ren, Vice President of Medicilon’s Chemical Department, gave a welcome speech to the guests, and the conference officially began!
Ms. Ruan Xiufang from the Drug Registration Office of Shanghai Food and Drug Administration delivered a keynote speech
Ms. Ruan Xiufang from the Drug Registration Office of Shanghai Food and Drug Administration delivered a keynote speech
Dr. Shi Li, CEO of Shanghai Zerun Biotechnology Co., Ltd. brings
Dr. Shi Li, CEO of Shanghai Zerun Biotechnology Co., Ltd. brings “Vaccine Preclinical Research and Clinical Application Strategy Sharing”
Dr. Gu Xingchu, pre-clinical vice president of Shanghai Medicilon brings a wonderful report on
Dr. Gu Xingchu, pre-clinical vice president of Shanghai Medicilon brings a wonderful report on “Monoclonal Antibodies-Important Fragments, Immunogenicity and Immunotoxicity”
Dr. Yu Qiang, CEO of Shengshi Tyco Biomedical Technology (Suzhou) Co., Ltd., brings
Dr. Yu Qiang, CEO of Shengshi Tyco Biomedical Technology (Suzhou) Co., Ltd., brings “Small Molecule Drug Preclinical Research and Clinical Application Strategy”
Dr. Zhao Yongxin, Chairman of Hangzhou Duoxi Biotechnology Co., Ltd., talked about
Dr. Zhao Yongxin, Chairman of Hangzhou Duoxi Biotechnology Co., Ltd., talked about “New monoclonal antibody-drug conjugate (ADC) anti-cancer drug creation”

The guests answered questions one by one on the questions raised by the participants, and the atmosphere was warm

Topic discussion session
Topic discussion session

From left to right: Dr. Chunlin Chen of Shanghai Medicilon Biopharmaceutical Co., Ltd., Chenyan Gao, Director of the Department of Biological Products, National Center for Drug Evaluation, Dr. Qiang Yu of Shengshitaike Biomedical Technology (Suzhou) Co., Ltd., Hangzhou Duoxi Biotech Dr. Yongxin Zhao from Shanghai Technology Co., Ltd., Dr. Shi Li from Shanghai Zerun Biotechnology Co., Ltd., Dr. Xiaobin Zhao from The WhiteOak Group, Dr. Jianguo Ma from Shanghai Medicilon Biopharmaceutical Co., Ltd., and Dr. Xingchu Gu from Shanghai Medicilon Biomedical Co., Ltd.

The Bio-forum sub-forum hosted by Medicilon has gone through four years and has been recognized and supported by more than a thousand industry colleagues. The research and development of new drugs has a long way to go. It is undoubtedly a thorny road for innovative drugs to go through structural design to the final approval. Medicilon, as a one-stop drug preclinical research and development service provider, is willing to help improve the level of new drug research and development in my country. Promote the healthy and orderly development of the industry!

Related Articles:

API process development of the new drug IND stage

Medicilon held the Preclincial and IND Declaration Seminar in Chengdu, China

Medicilon will hold The Preclinical Research for New Drug & IND-Enabling Strategy Summit

Relevant newsRelevant news